Windtree Therapeutics Stock Scheduled to Reverse Split on Monday, April 22nd (NASDAQ:WINT)

Windtree Therapeutics, Inc. (NASDAQ:WINT)’s stock is set to reverse split on the morning of Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 22nd.

Windtree Therapeutics Stock Performance

Shares of NASDAQ WINT traded down $0.06 during trading hours on Thursday, hitting $0.34. 1,789,008 shares of the company’s stock were exchanged, compared to its average volume of 280,849. Windtree Therapeutics has a 1-year low of $0.27 and a 1-year high of $7.79. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.40 and a quick ratio of 2.40. The stock has a market capitalization of $1.75 million, a price-to-earnings ratio of -0.05 and a beta of 0.61. The company’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.67.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research report on Wednesday, January 3rd.

Hedge Funds Weigh In On Windtree Therapeutics

Several large investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in Windtree Therapeutics by 54.1% in the 2nd quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock valued at $151,000 after acquiring an additional 126,949 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in Windtree Therapeutics by 97.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock valued at $36,000 after acquiring an additional 104,934 shares in the last quarter. Millennium Management LLC raised its holdings in Windtree Therapeutics by 411.1% in the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock valued at $33,000 after acquiring an additional 64,232 shares in the last quarter. Vanguard Group Inc. acquired a new position in Windtree Therapeutics in the 3rd quarter valued at approximately $40,000. Finally, Virtu Financial LLC acquired a new position in Windtree Therapeutics in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.